The human papillomavirus type 58 E7 oncoprotein modulates cell cycle regulatory proteins and abrogates cell cycle checkpoints

Virology

Volumn 397, Issue 1, 2010, Pages 139-144

  Zhang, Weifang ^a,b   Li, Jing ^b   Kanginakudru, Sriramana ^a   Zhao, Weiming ^b   Yu, Xiuping ^b   Chen, Jason J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cdk2; Checkpoint; E7; HPV 58; p130; p21; p53; Rb

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 2; PROTEIN E7; PROTEIN P130; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNOBLOTTING; KERATINOCYTE; LIFESPAN; MITOSIS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; UTERINE CERVIX CANCER;

CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CRK-ASSOCIATED SUBSTRATE PROTEIN; CYCLIN-DEPENDENT KINASE 2; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HOST-PATHOGEN INTERACTIONS; HUMANS; KERATINOCYTES; NUCLEAR PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; TUMOR SUPPRESSOR PROTEINS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 58;

EID: 73949091825     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.10.051     Document Type: Article

References (52)

1. Andreassen P.R., Lohez O.D., Lacroix F.B., and Margolis R.L. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol. Biol. Cell 12 5 (2001) 1315-1328
2. Banerjee N.S., Genovese N.J., Noya F., Chien W.M., Broker T.R., and Chow L.T. Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes. J. Virol. 80 13 (2006) 6517-6524
3. Burkhart D.L., and Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8 9 (2008) 671-682
4. Chen J., and Stubbe J. Bleomycins: towards better therapeutics. Nat. Rev. Cancer 5 2 (2005) 102-112
5. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl. 3 (2006) S3/26-34
6. Clifford G.M., Smith J.S., Aguado T., and Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89 1 (2003) 101-105
7. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 24 17 (2005) 2796-2809
8. Demers G.W., Foster S.A., Halbert C.L., and Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 4382-4386
9. Dimri G.P., Nakanishi M., Desprez P.Y., Smith J.R., and Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol. Cell. Biol. 16 6 (1996) 2987-2997
10. Dyson N., Guida P., Munger K., and Harlow E. Homologous sequences in adenovirus E1a and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66 (1992) 6893-6902
11. Fan X., and Chen J.J. Regulation of cell cycle progression and apoptosis by the papillomavirus E6 oncogene. Crit. Rev. Eukaryot. Gene Expr. 14 3 (2004) 183-202
12. Flores E.R., Allen-Hoffmann B.L., Lee D., and Lambert P.F. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 74 14 (2000) 6622-6631
13. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., and Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11 (1997) 2090-2100
14. Genovese N.J., Banerjee N.S., Broker T.R., and Chow L.T. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J. Virol. 82 10 (2008) 4862-4873
15. Gonzalez S.L., Stremlau M., He X., Basile J.R., and Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75 16 (2001) 7583-7591
16. He W., Staples D., Smith C., and Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J. Virol. 77 19 (2003) 10566-10574
17. Heilman S.A., Nordberg J.J., Liu Y., Sluder G., and Chen J.J. Abrogation of the postmitotic checkpoint contributes to polyploidization in human papillomavirus E7-expressing cells. J. Virol. 83 6 (2009) 2756-2764
18. Helt A.M., and Galloway D.A. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75 15 (2001) 6737-6747
19. Hickman E.S., Bates S., and Vousden K.H. Perturbation of the p53 response by human papillomavirus type 16 E7. J. Virol. 71 (1997) 3710-3718
20. Hiller T., Poppelreuther S., Stubenrauch F., and Iftner T. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol. Biomark. Prev. 15 7 (2006) 1262-1267
21. Hwang S.G., Lee D., Kim J., Seo T., and Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 277 4 (2002) 2923-2930
22. Jones D.L., and Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J. Virol. 71 4 (1997) 2905-2912
23. Jones D.L., Alani R.M., and Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11 (1997) 2101-2111
24. Khan S.H., and Wahl G.M. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58 3 (1998) 396-401
25. Kong L.J., Meloni A.R., and Nevins J.R. The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1. Mol. Cell 22 1 (2006) 63-71
26. Lacy S., and Whyte P. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes. Oncogene 14 20 (1997) 2395-2406
27. Lanni J.S., and Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18 2 (1998) 1055-1064
28. Levrero M., De Laurenzi V., Costanzo A., Gong J., Wang J.Y., and Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell. Sci. 113 Pt. 10 (2000) 1661-1670
29. Liu Y., Heilman S.A., Illanes D., Sluder G., and Chen J.J. p53-independent abrogation of a postmitotic checkpoint contributes to HPV E6-induced polyploidy. Cancer Res. 67 6 (2007) 2603-2610
30. Mansour M., Touka M., Hasan U., Bellopede A., Smet A., Accardi R., Gabet A.S., Sylla B.S., and Tommasino M. E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development. Virology 367 1 (2007) 1-9
31. McIntyre M.C., Ruesch M.N., and Laimins L.A. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 215 (1996) 73-82
32. McLaughlin-Drubin M.E., and Munger K. The human papillomavirus E7 oncoprotein. Virology 384 2 (2009) 335-344
33. McLaughlin-Drubin M.E., Huh K.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J. Virol. 82 17 (2008) 8695-8705
34. Morozov A., Shiyanov P., Barr E., Leiden J.M., and Raychaudhuri P. Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21. J. Virol. 71 (1997) 3451-3457
35. Muench P., Hiller T., Probst S., Florea A.M., Stubenrauch F., and Iftner T. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. Virology 387 2 (2009) 380-387
36. Nguyen C.L., and Munger K. Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 380 1 (2008) 21-25
37. Olaharski A.J., Sotelo R., Solorza-Luna G., Gonsebatt M.E., Guzman P., Mohar A., and Eastmond D.A. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis 27 2 (2006) 337-343
38. Parkin D.M., Louie K.S., and Clifford G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine 26 Suppl. 12 (2008) M1-M16
39. Ruesch M.N., and Laimins L.A. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J. Virol. 71 (1997) 5570-5578
40. Sablina A.A., Agapova L.S., Chumakov P.M., and Kopnin B.P. p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. Cell Biol. Int. 23 5 (1999) 323-334
41. Satyanarayana A., and Kaldis P. A dual role of Cdk2 in DNA damage response. Cell Div. 4 (2009) 9
42. Shin M.K., Balsitis S., Brake T., and Lambert P.F. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res. 69 14 (2009) 5656-5663
43. Stewart Z.A., and Pietenpol J.A. p53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol. 14 3 (2001) 243-263
44. Stewart Z.A., Leach S.D., and Pietenpol J.A. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol. 19 1 (1999) 205-215
45. Stoppler H., Hartman D.-H., Sherman L., and Schlegel R. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length. J. Biol. Chem. 272 20 (1997) 13332-13337
46. Tommasino M., Adamczewski J.P., Carlotti F., Barth C.F., Manetti R., Contorni M., Cavalieri F., Hunt T., and Crawford L. HPV 16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 8 (1993) 195-202
47. Westbrook T.F., Nguyen D.X., Thrash B.R., and McCance D.J. E7 abolishes raf-induced arrest via mislocalization of p21(Cip1). Mol. Cell. Biol. 22 20 (2002) 7041-7052
48. Xiong Y., Hannon G., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
49. Yamamoto A., Kumakura S., Uchida M., Barrett J.C., and Tsutsui T. Immortalization of normal human embryonic fibroblasts by introduction of either the human papillomavirus type 16 E6 or E7 gene alone. Int. J. Cancer 106 3 (2003) 301-309
50. Zehbe I., Ratsch A., Alunni-Fabbroni M., Burzlaff A., Bakos E., Durst M., Wilander E., and Tommasino M. Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions. Oncogene 18 13 (1999) 2201-2211
51. Zhang B., Chen W., and Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Natl. Acad. Sci. U. S. A. 103 2 (2006) 437-442
52. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 5 (2002) 342-350